Adding Immunotherapy to Head and Neck Cancer Treatment Fails to Improve PFS
October 19th 2016Adding a Toll-like receptor 8 agonist (TLR8) to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) failed to improve progression-free survival (PFS).
Read More
The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer
October 11th 2016Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.
Read More
High Response Rates Observed with Ipilimumab Plus Nivolumab in Advanced Melanoma
October 11th 2016Combined ipilimumab and nivolumab administered pre- and post-surgery reduced the tumor burden in patients with Stage III B/C melanoma, according to first results from the OpACIN trial reported at the ESMO 2016 Annual Congress.
Read More
Nivolumab Misses PFS Endpoint in NSCLC Compared With Chemotherapy
October 11th 2016Results of a recent randomized trial showed first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.
Read More
Results of Phase II mUC Trial Support Approval of Nivolumab Applications
October 11th 2016Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency (EMA) applications were reported at the 2016 ESMO Congress.
Read More
Neoadjuvant Nivolumab Achieves Tumor Regression in 40% of NSCLC Study Patients
October 11th 2016Almost 40% of patients with resected early-stage non–small cell lung cancer (NSCLC) had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.
Read More
Anthracycline-Based Chemotherapy Produces Significant Survival Benefit in Sarcoma
October 10th 2016A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy, according to a study presented at the 2016 ESMO Congress.
Read More
PFS Three Times Longer With Ceritinib Than With Chemotherapy in ALK+ NSCLC
October 10th 2016Progression-free survival (PFS) was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced <em>ALK</em>-positive non–small cell lung cancer (NSCLC) who progressed after first-line crizotinib.
Read More
Significant Disparities in Access to Novel Agents For Patients With Melanoma
October 9th 2016Lidija Kandolf Sekulovic, MD, PhD, associate professor of Dermatology, Military Medical Academy in Belgrade, Serbia, discusses a recently published survey during an interview at the 2016 ESMO Congress. The survey found that several thousand patients with metastatic melanoma in Europe do not have access to new, life-saving agents in this field.
Read More
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
October 9th 2016Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.
Read More
Pembrolizumab Data Will Change Management of NSCLC
October 9th 2016Single-agent pembrolizumab (Keytruda) reduced the risk of death by 40% and improved progression-free survival (PFS) by 4.3 months compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥50% of cells, according to findings from the phase III KEYNOTE-024 trial.
Read More
Regorafenib Has Potential to Become Second-Line Standard of Care in HCC
October 8th 2016The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma (HCC) who are unsuitable for loco-regional therapy and have progressed on sorafenib.
Read More
Results of the MONALEESA-2 Study in Advanced Breast Cancer
October 8th 2016Gabriel Hortobagyi, MD, professor of Medicine, University of Texas, MD Anderson Cancer Center, discusses the major findings of the MONALEESA-2 study in advanced breast cancer, during an interview at the 2016 ESMO Congress.
Read More
Thousands of Metastatic Melanoma Patients in Europe Without Access to Novel Agents
October 8th 2016Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives, according to a survey presented at the 2016 ESMO Congress.
Read More
Factors Associated With Discordance in Mutation Status in Metastatic CRC
October 8th 2016Mikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.
Read More
Results and Key Takeaways from the Final OS Analysis of the CLEOPATRA Study
October 2nd 2014Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study.
Read More
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
October 1st 2014Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
Read More
Afatinib Improves PFS in Advanced Head and Neck Cancer
September 29th 2014Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.
Read More